Wealthspire Advisors LLC Acquires Shares of 2,686 Gilead Sciences, Inc. (NASDAQ:GILD)

Wealthspire Advisors LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,686 shares of the biopharmaceutical company’s stock, valued at approximately $248,000.

A number of other large investors have also recently made changes to their positions in GILD. TCW Group Inc. raised its position in shares of Gilead Sciences by 1.1% in the fourth quarter. TCW Group Inc. now owns 30,277 shares of the biopharmaceutical company’s stock worth $2,797,000 after buying an additional 343 shares in the last quarter. Fisher Funds Management LTD bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $6,096,000. First Horizon Advisors Inc. grew its stake in shares of Gilead Sciences by 6.0% in the fourth quarter. First Horizon Advisors Inc. now owns 291,278 shares of the biopharmaceutical company’s stock worth $26,905,000 after purchasing an additional 16,591 shares during the last quarter. Pinnacle Financial Partners Inc bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $265,000. Finally, Oxbow Advisors LLC boosted its position in Gilead Sciences by 0.6% during the 4th quarter. Oxbow Advisors LLC now owns 71,941 shares of the biopharmaceutical company’s stock valued at $6,645,000 after acquiring an additional 450 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Up 1.4 %

Shares of NASDAQ GILD opened at $111.99 on Friday. The company has a 50-day moving average of $96.98 and a 200 day moving average of $89.65. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $112.57. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a market cap of $139.57 billion, a PE ratio of 302.68, a P/E/G ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.82%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of analyst reports. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Piper Sandler upped their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. UBS Group increased their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Truist Financial raised their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Finally, Royal Bank of Canada raised their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $102.08.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 293,356 shares of company stock worth $29,166,240. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.